Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron

References

• HawkinsRGrunbergSChemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomesClin J Oncol Nurs200913546419193549
   PubMed Web of Science ®Google Scholar
• De MoorCCunninghamRSImproving the functional status of patients with cancer by more effectively preventing chemotherapy induced nausea and vomiting (CINV): a comparison of palonosetron (PALO) vs ondansetron (OND) or dolasetron (DOL)J Support Oncol200532526
   Google Scholar
• HeskethPJChemotherapy-induced nausea and vomitingN Engl J Med20083582482249418525044
   PubMed Web of Science ®Google Scholar
• NaeimADySMLorenzKASanatiHWallingAAschSMEvidence-based recommendations for cancer nausea and vomitingJ Clin Oncol2008263903391018688059
   PubMed Web of Science ®Google Scholar
• CelioLDenaroACanovaSGevorgyanABajettaEClinical update on palonosetron in the management of chemotherapy-induced nausea and vomitingTumori20089444745218822676
   PubMed Web of Science ®Google Scholar
• HerrstedtJAntiemetics: an update and the MASCC guidelines applied in clinical practiceNat Clin Pract Oncol20085324318097455
   PubMedGoogle Scholar
• HeskethPJKrisMGGrunbergSMProposal for classifying the acute emetogenicity of cancer chemotherapyJ Clin Oncol1997151031098996130
   PubMed Web of Science ®Google Scholar
• GrunbergSMOsobaDHeskethPJEvaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity an updateSupport Care Cancer200513808415599601
   PubMed Web of Science ®Google Scholar
• RoilaFHeskethPJHerrstedtJAntiemetic Subcommitte of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus ConferenceAnn Oncol200617202816314401
   PubMed Web of Science ®Google Scholar
• RubensteinEBSlusherBSRojasCNavariRMNew approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigationsCancer J20061234134717034670
   PubMed Web of Science ®Google Scholar
• HornbyPJCentral neurocircuitry associated with emesisAm J Med20011118A106S112S11749934
   PubMed Web of Science ®Google Scholar
• TriggMEInversoDMNausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimensBone Marrow Transplant20084250150618724391
   PubMed Web of Science ®Google Scholar
• ThompsonAJLummisSCRThe 5-HT3 receptor as a therapeutic agentExpert Opin Ther Targets20071152754017373882
   PubMed Web of Science ®Google Scholar
• HietalaJNymanMJEskolaOVisualization and quantification of neurokinin-1 (NK1) receptors in the human brainMol Imaging Biol2005726227216155744
   PubMed Web of Science ®Google Scholar
• CoatesAAbrahamSKayeSBOn the receiving patient perception of the side-effects of cancer chemotherapyEur J Cancer Clin Oncol1983192032086681766
   PubMedGoogle Scholar
• GriffinAMButowPNCoatesASOn the receiving patient perceptions of the side effects of cancer chemotherapy in 1993Ann Oncol199671891958777177
   PubMed Web of Science ®Google Scholar
• CohenLDe MoorCEisenbergPDelayed chemotherapy-induced nausea and vomiting (CINV) remains a problem and significantly interferes with daily function (DF) in patients receiving emetogenic chemotherapy (CT) in the United StatesProc Am Soc Clin Oncol200322739
   Google Scholar
• GelingOEichlerHGShould 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implicationsJ Clin Oncol2005231289129415718327
   PubMed Web of Science ®Google Scholar
• GirishCManikandanSAprepitant: a substance P antagonist for chemotherapy-induced nausea and vomitingIndian J Cancer200744253017401221
   PubMedGoogle Scholar
• RoilaFDonatiDTamberiSMarguttiGDelayed emesis: incidence, pattern, prognostic factors and optimal treatmentSupport Care Cancer200210889511862498
   PubMed Web of Science ®Google Scholar
• KrisMGHeskethPJMarkRAmerican Society of Clinical Oncology Guidelines for Antiemetics in Oncology: Update 2006J Clin Oncol2006242932294716717289
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN)Clinical practice guidelines in oncology. Antiemesis. Version 12009 http://www.nccn.org. Accessed January 11, 2009.
   Google Scholar
• NavariRMPrevention of emesis from multiple-day and high-dose chemotherapy regimensJ Nat Compr Canc Netw200755159
   PubMedGoogle Scholar
• JordanKHinkeAGrotheyAA meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesisSupport Care Cancer2007151023103317205281
   PubMed Web of Science ®Google Scholar
• GrallaRLichinitserMVan Der VegtSPalonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetronAnn Oncol2003141570157714504060
   PubMed Web of Science ®Google Scholar
• EisenbergPFigueroa-VadilloJZamoraR99-04 Palonosetron Study Group. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetronCancer2003982473248214635083
   PubMed Web of Science ®Google Scholar
• SaitoMAogiKSekineIPalonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trialLancet Oncol20091011512419135415
   PubMed Web of Science ®Google Scholar
• HeskethJPNew treatment options for chemotherapy-induced nausea and vomitingSupport Care Cancer20041255055515232725
   PubMed Web of Science ®Google Scholar
• RojasCStathisMThomasAGPalonosetron exhibits unique molecular interactions with the 5-HT3 receptorAnesth Analg200810746947818633025
   PubMed Web of Science ®Google Scholar
• FDA Product information http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=ALOXI. Accessed March 18, 2009.
   Google Scholar
• European Product Information 29/01/2009 Aloxi-H-C-563-II-13. http://www.emea.europa.eu/humandocs/Humans/EPAR/aloxi/aloxi.htm. Accessed March 18, 2009.
   Google Scholar
• MorganrothJParisiSSpinelliTMoresinoCThornMCullenMTHigh-dose palonosetron does not alter ECG parameters including QTc interval in healthy subjects: results of a dose-response, double-blind, randomized, parallel E14 study of palonosetron vs moxifloxacin or placeboPresentation at the 14th European Conference of Clinical Oncology (ECCO)September 23–27, 2007
   Google Scholar
• AaproMSPalonosetron as an anti-emetic and anti-nausea agent in oncologyTher Clin Risk Manag200731009102018516316
   PubMedGoogle Scholar
• AaproMSGrunbergSMManikhasGMA phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapyAnn Oncol2006171441144916766588
   PubMed Web of Science ®Google Scholar
• YuZLiuWWangLThe efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trialSupport Care Cancer2009179910218825421
   PubMed Web of Science ®Google Scholar
• RubensteinEBGrallaRJEisenbergPPalonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV): combined results of two phase III trialsProc Am Soc Clin Oncol200322729
   Web of Science ®Google Scholar
• GrunbergSMKoellerJMPalonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesisExpert Opin Pharmacother200342297230314640928
   PubMed Web of Science ®Google Scholar
• GrunbergSVanden BurgtJBerrySPrevention of delayed nausea and vomiting (D-CINV): carryover effect analysis of pooled data from 2 phase III studies of palonosetron (PALO)J Clin Oncol200422A8051
   Web of Science ®Google Scholar
• LorussoVSpedicatoAPetrucelliLSingle dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary resultsSupport Care Cancer2009 DOI 10.1007/s00520-009-0611-9.
   Web of Science ®Google Scholar
• GiulianiFCilentiGNugnesIPalonosetron for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic adjuvant folfox-4 regimen in colorectal cancer (CRC) patients: a phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM)Eur J Cancer Suppl20086102106
   Web of Science ®Google Scholar
• EinhornLHBromesMJDreicerRPalonosetron plus dexamethasone for prevention of chemotherapy induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancerSupport Care Cancer2007151293130017436025
   PubMed Web of Science ®Google Scholar
• MussoMScaloneRBonannoVPalonosetron (Aloxi®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapySupport Care Cancer20091720520918839220
   PubMed Web of Science ®Google Scholar
• GroteTHajdenbergJCartmellAFergusonSGinkelACharuVCombination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitantJ Support Oncol2006440340817004515
   PubMedGoogle Scholar
• HerringtonJDJaskiewiczADSongJRandomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomitingCancer20081122080208718327813
   PubMed Web of Science ®Google Scholar
• GrunbergSMDuganMMussHEffectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapySupport Care Cancer20091758959419037667
   PubMed Web of Science ®Google Scholar
• NavariRMEinhornLHLoehrerPJA phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomitingSupport Care Cancer20051352953415700131
   PubMed Web of Science ®Google Scholar
• NavariRMEinhornLHLoehrerPJSrA phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group studySupport Care Cancer2007151285129117375339
   PubMed Web of Science ®Google Scholar
• CaroMMLavianoAPichardCNutritional intervention and quality of life in adult oncology patientsClinic Nutr200726289301
   PubMed Web of Science ®Google Scholar